(Corrects Swiss francs sales drop to 1%, not 3%, in second paragraph)
ZURICH (Reuters) - Swiss drugmaker Roche said first-quarter revenue rose 3% at constant exchange rates, as its sales of COVID-19 diagnostics helped offset a slump in the mainstay drug business.
Sales were 14.9 billion Swiss francs ($16.26 billion), which in Swiss francs was down 1% from 15.1 billion francs in the year-earlier period, Roche said in a statement. The Basel-based company, which does not report quarterly profit, said the strong Swiss franc dragged down revenue.
The Basel-based company still expects current-year sales growth in the low- to mid-single digit range at constant exchange rates, with similar core earnings per share growth.
(Reporting by John Miller; Editing by Michael Shields)
This article has been provided by a DearWallstreet contributor. All content submitted by this author represent their personal opinions, and should be considered as such for entertainment purpose only. All opinions expressed are those of the writer, and may not necessarily represent fact, opinions, or bias of DearWallstreet.